Why POC Diagnostics Are Growing So Fast

Three converging forces are driving POC diagnostics growth: (1) Clinical demand for speed — emergency medicine, infectious disease, and chronic disease management all benefit from results in minutes rather than hours; (2) Healthcare decentralisation — global trends toward primary care, home care, and telemedicine require diagnostic capability outside the central laboratory; (3) Technology maturation — advances in microfluidics, biosensors, miniaturised electronics, and smartphone connectivity have made POC devices smaller, cheaper, and more accurate than ever before. COVID-19 rapid antigen tests demonstrated to the world that high-volume, low-cost POC diagnostics could operate at scale — and that appetite has not diminished.

Key POC Diagnostic Categories in 2026

The most commercially significant POC diagnostic categories are: Blood glucose monitoring (the largest established POC category — CGMs are transforming this further); Cardiac biomarkers (troponin, BNP — enabling AMI diagnosis in the ambulance and emergency department); Infectious disease rapid tests (influenza, RSV, COVID-19, malaria, HIV, strep A); Haematology analysers (complete blood count in primary care and pharmacy settings); Coagulation monitoring (INR for anticoagulation management, enabling home monitoring); Blood gas and electrolyte analysers (critical care POC for ICU and emergency); Urinalysis (dipstick and automated strip readers); Molecular diagnostics — PCR-equivalent results in 30–60 minutes at the point of care.

Regulatory Classification of POC Devices

POC diagnostic devices are regulated as In Vitro Diagnostic devices under EU IVDR (Class B, C, or D depending on clinical risk) and as Class I, II, or III devices under FDA CLIA regulations. POC devices intended for use by untrained users (self-test or lay use) face additional usability requirements — IEC 62366 usability engineering evidence is mandatory, and clinical performance must be validated in the intended user population (not just trained laboratory technicians). For home-use POC devices, both EU IVDR self-test classification rules and FDA OTC (over-the-counter) pathways apply, with distinct and demanding requirements for lay-user labelling and IFU design.

Connectivity: The POC Differentiator

Modern POC devices are increasingly defined by their connectivity capability. A POC analyser that transmits results directly to the patient's EHR, alerts the clinical team via a mobile notification, and uploads data to a cloud analytics platform is fundamentally more valuable than an identical device that only displays a result on a screen. Key connectivity requirements for competitive POC products in 2026 include: Bluetooth LE for smartphone pairing, HL7 FHIR for EHR integration, LIS (Laboratory Information System) connectivity for institutional devices, and GDPR/HIPAA-compliant cloud data management. Manufacturers who treat connectivity as a software module added on top of an existing device will be outcompeted by those who design connectivity as a core product feature.

Emerging Markets: The POC Growth Engine

While POC diagnostics are growing strongly in developed markets, the highest growth rates are in emerging markets — Southeast Asia, Africa, South Asia, and the Middle East. In these markets, POC diagnostics address a genuine structural need: laboratories are scarce, cold chains are unreliable, and most clinical decisions must be made without laboratory support. Malaria rapid tests in sub-Saharan Africa, TB molecular diagnostics in India, and HbA1c monitoring for diabetes management across Southeast Asia are POC applications with massive addressable markets. Turkish manufacturers targeting these markets should prioritise affordable, rugged, battery-operable POC devices designed for use in resource-limited settings.

Turkish Manufacturer Opportunities

Turkey's well-developed electronics manufacturing, plastic injection moulding, and diagnostic reagent chemistry capabilities create a solid foundation for POC device manufacturing. Key opportunities include: reagent strip manufacturing for urinalysis and blood glucose — Turkey has existing chemistry manufacturing capability; rapid test cartridge assembly — the lateral flow assay platform is technically accessible and Turkey has existing immunochemistry expertise; handheld analyser casing and assembly — Turkish electronics manufacturing can supply OEM components or complete devices; distribution of internationally developed POC platforms in Turkey's priority export markets — becoming the regional access partner for a foreign POC company.

Conclusion

Point-of-care diagnostics represent one of the most democratising trends in modern healthcare — making clinical-quality diagnostic information available wherever patients and clinicians need it. Turkish medical device manufacturers who invest in POC technology, whether through original development, OEM partnerships, or component manufacturing, are positioning themselves in one of medtech's highest-growth, highest-impact product categories.